The phase 2 savolitinib trial offers three important insights for clinical practice. First, the drug demonstrates promising clinical efficacy specifically in MET-amplified gastric and gastroesophageal junction tumors, a molecularly defined patient subset. Second, this represents a precision medicine approach that prioritizes biomarker-driven patient selection—a methodology that has become essential for optimizing cancer treatment outcomes. Third, the trial results mark meaningful progress toward a new treatment option for gastric cancer patients with limited therapeutic alternatives.
These findings underscore the critical value of comprehensive molecular profiling in gastric cancer diagnosis and treatment planning. Clinicians should recognize that MET amplification testing may identify patients who could benefit from targeted therapy with savolitinib as additional clinical data emerge. The structured trial design, incorporating both exploratory and pivotal phases, demonstrates best practices in precision oncology development.
Read the full article on GMJ Newsroom.
Was this article helpful?
